The Safety and Efficacy Study of Regorafenib (CT) Compared With Regorafenib (STIVARGA) in Patients With Solid Tumors
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 19 Sep 2015
At a glance
- Drugs Regorafenib (Primary)
- Indications Solid tumours
- Focus Therapeutic Use
- 09 Jun 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 04 May 2015 New trial record
- 03 May 2015 Planned primary completion date changed from 1 Apr 2015 to 1 Apr 2018, according to ClinicalTrials.gov record.